Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Arthritis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Arthritis Other
    Canakinumab Approved in EU for Patients 4 Years and Older With Cryopyrin-Associated Periodic Syndromes - (DGNews)
    Canakinumab Gives Faster, Greater Pain Relief in Refractory Gout Patients: Presented at ACR/ARHP - (DGDispatch)
    Previous Urate-Lowering Therapy Plus Febuxostat Lowers Urate Levels, Number of Flares in Patients With Gout: Presented at ACR/ARHP - (DGDispatch)
    Canakinumab Therapy Shows Promise for Systemic Juvenile Idiopathic Arthritis: Presented at AAP - (DGDispatch)
    New Interleukin-12/23 Monoclonal Antibody Effective Against Moderate to Severe Psoriasis: Presented at EADV - (DGDispatch)

    News archive

     Recent webcasts/CME - Arthritis Other
      Molecular Mechanism of Cardiovascular Disease in Inflammatory Arthritis
      Getting to the Root of Gout and Hyperuricemia: Core Principles in Diagnosis and Management for Rheumatologists
      Ankylosing Spondylitis
      Psoriatic Arthritis
      The Epidemiology of Increased Cardiovascular Death in Inflammatory Arthritis

      Webcasts/CME archive

       Recent cases - Arthritis Other
        Papular Xanthomas and Erosive Arthritis in a 3 Year Old Girl, is This a New MRH Variant?
        Idiopathic Destructive Arthritis of the Shoulder
        Superior Dislocation of the Patella: A Case Report
        Concurrent Reactive Arthritis and Myelitis - A Case Report
        Infectious Arthritis of the Knee Caused by Mycobacterium Terrae: A Case Report

        Cases archive
          




        my personal edition > arthritis other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Infliximab Safe For Patients With Spondyloarthropathy Despite Some Occurrence Of Infection

        A DGReview of :"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?"
        Annals of the Rheumatic Diseases (ARD Online)

        09/03/2003
        By Deanna M Green, PhD


        Infliximab has a positive safety profile in patients with spondyloarthropathy (SpA); however patients should be carefully monitored for potential infection, according to a recent Belgian study.

        Anti-tumour necrosis factor agents, such as infliximab, are often used to treat rheumatoid arthritis and Crohn's disease. However, safety concerns have been raised since the drugs' inhibitory effects on the immune system could lead to severe infections, malignancies, and immune mediated diseases.

        This is of particular concern in patients with SpA, since the pathogenesis of this disease has been linked to a defective host defence. However, recent studies have demonstrated effective results with infliximab treatment in SpA patients.

        Dr. Dominique Baeten and colleagues at the Ghent University Hospital, Ghent, Belgium, evaluated the long term safety profile of infliximab in patients with SpA by conducting a systematic review of adverse events reported by these patients.

        The cohort study included 107 patients (73 men and 34 women) between the ages of 26 and 73 with active SpA. Patients received intravenous infliximab (5 mg/kg) at start of study, week 2 and week 6. Serious and treatment-related adverse events were evaluated over a total of 191.5 patient years.

        Overall, 20 serious or treatment-related adverse events were reported, including 14 infectious adverse events.

        Of 10 serious events, 8 were severe infections, namely 2 disseminated tuberculosis and 3 retropharyngeal abscesses. Other serious non-infectious events included a spinocellular skin carcinoma and an infusion reaction.

        Ten minor treatment related events occurred, including clear bacterial focus, skin eruptions, and a mild infusion reaction. None required hospital admission and all recovered with antibiotics.

        Although no cases of demyelinating disease or lupus-like syndrome were reported, 3 patients with ankylosing spondylitis and no history of psoriasis developed palmoplantar pustulosis during treatment.

        Overall, infliximab discontinuation was only necessary in 5 patients, all of whom experienced serious infections, and 92% of patients were continuing treatment at an average of 1.8 years.

        Dr. Baeten concludes that "although the global safety of infliximab in SpA is good compared with previous reports in rheumatoid arthritis and Crohn's disease, the occurrence of infections such as tuberculosis and retropharyngeal abscesses highlights the importance of careful screening and follow up."
        Ann Rheum Dis 2003 Sept;62:9:829-834. "Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send